Summary

Comprehensive update to the 2014 guideline and 2019 focused update for diagnosis and management of atrial fibrillation, introducing a new stage-based AF classification (Stages 1–4) emphasizing AF as a disease continuum. Major changes include upgrading catheter ablation to Class 1 first-line therapy in selected patients (including HFrEF), upgrading LAA occlusion to Class 2a for long-term anticoagulation contraindications, emphasizing early rhythm control, prescriptive lifestyle/risk factor modification, and refined recommendations for device-detected AF based on episode duration and CHA2DS2-VASc score.

Key Recommendations

Use CHA2DS2-VASc as the preferred validated clinical risk score; recommend oral anticoagulation when annual thromboembolic risk is ≥2% (CHA2DS2-VASc ≥2 in men, ≥3 in women); reasonable when intermediate risk (~1–2%, CHA2DS2-VASc 1 in men, 2 in women).
DOACs are preferred over warfarin for stroke prevention in eligible AF patients; warfarin remains first-line for moderate-to-severe rheumatic mitral stenosis or mechanical heart valves.
Catheter ablation is Class 1 as first-line rhythm control in selected younger, symptomatic patients with paroxysmal AF and in appropriate patients with HFrEF.
Early rhythm control within 1 year of AF diagnosis reduces composite cardiovascular death, stroke, and hospitalization (EAST-AFNET 4); pursue early in symptomatic and selected asymptomatic patients.
Comprehensive lifestyle/risk factor modification (≥10% weight loss if BMI ≥27, moderate aerobic exercise ~210 min/week, alcohol ≤3 drinks/week or abstinence, smoking cessation, BP <130/80, glycemic control, OSA evaluation/treatment) is a pillar of AF management.
For device-detected atrial high-rate episodes ≥24 hours with elevated stroke risk (CHA2DS2-VASc ≥2), oral anticoagulation is reasonable; episodes <5 minutes do not require anticoagulation; episodes 5 min–24 hours require individualized decision.
Percutaneous LAA occlusion is reasonable (Class 2a) in patients with AF and long-term contraindication to anticoagulation due to nonreversible cause.
Surgical LAA occlusion is recommended in AF patients with CHA2DS2-VASc ≥2 undergoing cardiac surgery, in addition to continued oral anticoagulation.
For AF with ACS/PCI: dual therapy (DOAC + P2Y12 inhibitor) is preferred over triple therapy after a short period (≤1 week) of triple therapy to reduce bleeding.
Anticoagulation around cardioversion: ≥3 weeks therapeutic anticoagulation before and ≥4 weeks after cardioversion regardless of CHA2DS2-VASc, or TEE-guided strategy; for AF <12–24 hours with low CHA2DS2-VASc, risk is lower.
In AF with HFrEF, catheter ablation is Class 1 to improve symptoms, LVEF, and reduce mortality/HF hospitalization; amiodarone or dofetilide are preferred antiarrhythmics; avoid class IC agents, dronedarone, and sotalol.
For preexcited AF (WPW), avoid AV nodal blockers (digoxin, verapamil, diltiazem, beta-blockers, amiodarone IV); use ibutilide or procainamide if hemodynamically stable, DCCV if unstable; AP ablation is definitive therapy.

Thresholds & Doses

Stroke risk thresholds for OAC: high ~>2%/y, intermediate ~1–2%/y, low ~<1%/y; CHA2DS2-VASc ≥2 (men) or ≥3 (women) generally warrants anticoagulation.
Apixaban 5 mg BID; reduce to 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, SCr ≥1.5 mg/dL.
Dabigatran 150 mg BID (CrCl >30 mL/min); 75 mg BID for CrCl 15–30 mL/min; contraindicated CrCl <15.
Rivaroxaban 20 mg daily (CrCl >50); 15 mg daily for CrCl 15–50 mL/min, taken with largest meal.
Edoxaban 60 mg daily (CrCl >50 to ≤95); 30 mg daily for CrCl 15–50; contraindicated CrCl >95 or <15.
Warfarin INR target 2.0–3.0; bleeding risk rises notably with INR >4.
Idarucizumab 5 g IV (two 2.5 g vials) reverses dabigatran; andexanet alfa low-dose 400 mg bolus + 4 mg/min × 120 min or high-dose 800 mg bolus + 8 mg/min × 120 min for apixaban/rivaroxaban-associated bleeding.
4-factor PCC for warfarin reversal: INR 2–<4: 25 U/kg; INR 4–6: 35 U/kg; INR >6: 50 U/kg.
DOAC interruption before surgery: low bleeding risk procedure 1 day; high bleeding risk 2 days (4 days for dabigatran with CrCl 30–50). Warfarin held 5 days.
Rate control targets: lenient resting HR <110 bpm acceptable in many patients (RACE II); stricter <80 bpm at rest for symptomatic AF, tachycardia-induced cardiomyopathy, ICD, or CRT recipients.
AF burden definitions: paroxysmal ≤7 days; persistent >7 days; long-standing persistent >12 months; permanent (joint decision to stop rhythm control).
Device-detected AHRE thresholds: <5 min likely artifact/other; >6 min to 24 h intermediate; ≥24 h significant stroke risk warranting OAC consideration if CHA2DS2-VASc ≥2.
Cardioversion timing rule: if AF >48 hours or unknown duration, 3 weeks therapeutic anticoagulation pre-cardioversion or TEE; continue ≥4 weeks postcardioversion.
Weight loss target: ≥10% body weight loss in overweight/obese (BMI >27) AF patients to reduce AF burden, recurrence, and progression.
Exercise prescription: 210 minutes/week moderate-to-vigorous aerobic exercise to reduce AF burden.
Alcohol: ≤3 standard drinks/week or abstinence reduces AF burden/recurrence; risk increases linearly with intake.
BP target in AF: intensive control <130/80 mm Hg (SPRINT-based <120 mm Hg systolic reduces incident AF).
Ibutilide dose for cardioversion: 1 mg IV over 10 min if ≥60 kg (0.01 mg/kg if <60 kg); may repeat once; avoid if LVEF ≤40%.
Flecainide pill-in-pocket: 200 mg if <70 kg, 300 mg if ≥70 kg, single oral dose; propafenone 450 mg if <70 kg, 600 mg if ≥70 kg.
Amiodarone IV: 150 mg over 10 min, then 1 mg/min × 6 h, then 0.5 mg/min × 18 h; oral load total 6–10 g, then 200 mg daily maintenance.
Dofetilide: 500 μg BID (CrCl >60), 250 μg BID (CrCl 40–60), 125 μg BID (CrCl 20–40); contraindicated CrCl <20; requires 3-day inpatient initiation with continuous ECG monitoring.
Sotalol: 80–160 mg BID (CrCl >60); 80–160 mg daily (CrCl 40–60); contraindicated CrCl <40; requires inpatient initiation.
Digoxin therapeutic serum concentration: 0.5–0.9 ng/mL (concentrations ≥1.2 ng/mL associated with increased mortality).
Catheter ablation peri-procedure: uninterrupted OAC preferred; oral anticoagulation continued ≥2 months postablation regardless of CHA2DS2-VASc.
Class III obesity (BMI ≥40): DOACs preferred over warfarin based on observational data; warfarin reasonable after bariatric surgery due to absorption concerns.

Citations

Top 10 Take-Home Messages — major updates including AF staging, Class 1 ablation indication, LAAO upgrade
Section 2.2.1 (AF Classification) and Figure 4 — new AF stages framework
Section 6.1 and Table 8 — CHA2DS2-VASc, ATRIA, GARFIELD-AF risk scores
Section 6.3.1 and Figure 10 — antithrombotic therapy recommendations and DOAC vs warfarin
Section 6.4.1 and Figure 12 — device-detected AHRE management by duration and CHA2DS2-VASc
Section 6.5.1 and Table 14 — percutaneous LAAO indications
Section 6.5.2 — LAAOS III trial supporting surgical LAA occlusion
Section 6.7 and Table 18 — periprocedural anticoagulation interruption timing
Section 7.1 and Table 20 — rate control targets (RACE II)
Section 8.1 and Section 8.4 — early rhythm control and catheter ablation as first-line (EAST-AFNET 4, EARLY-AF, STOP-AF First, CABANA)
Tables 21–25 — rate and rhythm control drug dosing and monitoring
Section 9.2 and Table 27 — AF management in HF including CASTLE-AF, CABANA-HF
Section 5.2 — comprehensive lifestyle and risk factor modification recommendations